ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310

Stock Information for ProMIS Neurosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference
ProMIS Neurosciences Announces Reverse Stock Split
ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights
ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group
ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights
ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.